Teachers Retirement System of The State of Kentucky Increases Holdings in DexCom, Inc. $DXCM

Key Points

• Teachers Retirement System of the State of Kentucky increased its DexCom stake by 74.1% in Q4, buying 101,800 shares to hold 239,205 shares worth about $15.88 million (≈0.06% of the company).
• DexCom beat quarterly estimates with $0.68 EPS vs. $0.65 expected and $1.26B revenue (up 13.1% YoY); analysts rate the stock a "Moderate Buy" with a consensus target of $86.50.
• Institutional investors own 97.75% of DexCom; the stock trades in the mid-$60s (52-week range $54.11–$89.98) with a market cap of $23.76 billion and a P/E of 29.32.

Teachers Retirement System of The State of Kentucky raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 74.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 239,205 shares of the medical device company's stock after buying an additional 101,800 shares during the quarter. Teachers Retirement System of The State of Kentucky owned approximately 0.06% of DexCom worth $15,876,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. SJS Investment Consulting Inc. boosted its position in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock valued at $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new position in DexCom during the third quarter worth about $29,000. CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after purchasing an additional 147 shares during the last quarter. ORG Partners LLC grew its stake in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company's stock valued at $34,000 after buying an additional 281 shares during the period. Finally, Spire Wealth Management increased its holdings in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company's stock worth $38,000 after buying an additional 305 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM opened at $61.57 on Monday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The company has a 50 day moving average price of $66.82 and a 200 day moving average price of $66.60. The stock has a market capitalization of $23.76 billion, a P/E ratio of 29.32, a PEG ratio of 1.20 and a beta of 1.55.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the company earned $0.45 earnings per share. The firm's quarterly revenue was up 13.1% compared to the same quarter last year. Equities research analysts forecast that DexCom, Inc. will post 2.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DXCM. Truist Financial reiterated a "buy" rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Evercore raised DexCom from an "in-line" rating to an "outperform" rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. Sanford C. Bernstein restated an "outperform" rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Barclays reiterated an "underweight" rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Finally, Citigroup raised their price objective on DexCom from $77.00 to $84.00 and gave the stock a "buy" rating in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $86.50.

Insider Activity

In related news, EVP Michael Jon Brown sold 1,700 shares of the business's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.